Core Insights - Gelteq Limited has announced a partnership with the Hong Kong Flag Football Program to integrate its hydration and sports performance formulations into training and competition for national teams [1][2] - The collaboration highlights the growing interest in high-performance sports programs in the region, supported by a recent sales agreement with Shenzhen Mana Health Management Co. Ltd. worth at least USD $1.3 million [2] - Gelteq's proprietary delivery technology is increasingly being adopted in both sports and wellness applications, driven by demand for research-based products that enhance athlete performance [3] Company Developments - Gelteq's gel-based formulations are designed to aid athletes in managing hydration, energy regulation, and recovery, and are already utilized by elite programs in Australia and Asia [6] - The partnership with Hong Kong's national teams marks a significant step in the development of American football in the region, as all three teams recently achieved their first official international victories [4] - The CEO of Gelteq emphasized the versatility of their gel-based platform and the company's commitment to supporting athlete performance through science-driven innovation [5] Industry Trends - Flag football is recognized as one of the fastest-growing team sports globally, with increasing participation among youth and adults due to its accessibility and low-contact nature [5] - The growth of flag football in the region is bolstered by rising investments in sports science and high-performance training [5] - Gelteq is actively exploring additional opportunities in the region to expand its sports product portfolio and advance commercial discussions regarding its gel-based platform [7]

Core Insights - Gelteq Limited has entered a three-year sales agreement with Shenzhen Mana Health Management Co. Ltd. to distribute consumer nutritional products in China, with minimum annual order commitments totaling approximately USD $1.3 million [1][3][5] - The agreement aims to expand Gelteq's nutritional product portfolio in China, leveraging Mana's established distribution network and digital presence [2][4] Company Overview - Gelteq is a biotechnology company based in Melbourne, Australia, specializing in gel-based oral delivery technologies for pharmaceuticals and consumer health products [6] - The company focuses on enhancing bioavailability, improving patient compliance, and enabling precise dosing through its proprietary gel formulation technology [6] Market Strategy - The partnership with Mana is part of Gelteq's strategy to penetrate the rapidly growing wellness and functional nutrition market in China [4][5] - Gelteq plans to introduce additional nutritional products that utilize its proprietary technology as part of this agreement [4] Distribution and Promotion - Mana will promote and sell a nutritional formulation primarily aimed at lowering sugar levels across its multichannel healthcare network in China [3][5] - The agreement is expected to generate predictable revenue and advance the adoption of Gelteq's platform in a strategically important market for nutritional products [5]

Core Insights - Gelteq Limited has announced preclinical findings that demonstrate the effectiveness, flexibility, and safety of its proprietary gel-based oral delivery systems, addressing significant challenges in pharmaceutical development [1][6]. Preclinical Study Results - Two preclinical studies showed a 300% increase in bioavailability of an oil-soluble compound in Gelteq's gel base compared to an existing FDA-approved reference product within the first hour, which is critical for rapid onset of action [2]. - Overall absorption of the oil-soluble compound improved by more than 20% over 24 hours when using Gelteq's gel base compared to the reference product [3]. - The gel platform enables controlled movement through the digestive system, targeted release, and effective absorption while ensuring full clearance of both the active pharmaceutical ingredients and the gel material [4]. Mechanism of Action - The gel disperses the active ingredient uniformly along the small intestine, enhancing absorption through mucoadhesive interactions and presenting the drug across a larger intestinal surface area [5]. - The gel's structural matrix allows for efficient transit and rapid early absorption of the active pharmaceutical ingredient, reinforcing its safety and compatibility with oral administration [6]. Industry Context - Over 40% of approved drugs and up to 90% of developmental candidates face issues with poor solubility and bioavailability, leading to significant annual investments in new technologies to address these challenges [7]. - Gelteq's platform offers a streamlined solution that may reduce developmental burdens, enhance bioavailability, and potentially revive previously shelved or challenging molecules [7]. Therapeutic Applications - Therapeutic areas likely to benefit from Gelteq's gel-based delivery system include neurology, inflammation and pain management, hormonal therapies, cardiovascular medicine, nutraceuticals, weight management, oncology, and veterinary health, where lipid-based or poorly soluble APIs are common [8]. Strategic Positioning - By enabling consistent absorption, targeted delivery, reduced reliance on excipients, and strong safety characteristics, Gelteq positions itself as a valuable development partner for pharmaceutical and nutraceutical companies looking to reformulate existing assets or tackle complex formulation challenges [9].

MELBOURNE, Australia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (Nasdaq: GELS) (“Gelteq”) today announced that Nathan Givoni, its Chief Executive Officer, will present at the Q4 Investor Summit Virtual on December 9, 2025, where he will share updates on Gelteq’s growth strategy, market positioning, and upcoming catalysts. The Investor Summit is an exclusive virtual event connecting investors with disruptive small and microcap companies. This quarter’s event highlights MicroCap companies with compelli ...

Core Insights - Premarket trading is showing notable activity with early price movements indicating potential opportunities before the market opens [1] Premarket Gainers - Mawson Infrastructure Group Inc. (MIGI) is up 10% at $5.65 [3] - Mingteng International Corporation Inc. (MTEN) is up 9% at $1.88 [3] - Barnwell Industries, Inc. (BRN) is up 9% at $1.20 [3] - Amentum Holdings, Inc. (AMTM) is up 8% at $27.57 [3] - Antelope Enterprise Holdings Limited (AEHL) is up 8% at $2.75 [3] - Protagenic Therapeutics, Inc. (PTIX) is up 8% at $2.43 [3] - Envirotech Vehicles, Inc. (EVTV) is up 8% at $1.18 [3] - Vir Biotechnology, Inc. (VIR) is up 6% at $6.49 [3] - Zoom Communications Inc. (ZM) is up 5% at $82.73 [3] - Core AI Holdings (CHAI) is up 5% at $2.68 [3] Premarket Losers - Foxx Development Holdings Inc. (FOXX) is down 13% at $4.00 [4] - Jaguar Health, Inc. (JAGX) is down 11% at $1.13 [4] - AlphaTON Capital Corp. (ATON) is down 7% at $2.54 [4] - Semtech Corporation (SMTC) is down 6% at $65.81 [4] - Cypherpunk Technologies Inc. (CYPH) is down 5% at $1.73 [4] - SunPower Inc. (SPWR) is down 5% at $1.59 [4] - Visionary Holdings Inc. (GV) is down 4% at $1.23 [4] - Gelteq Limited (GELS) is down 4% at $1.01 [4] - Capricor Therapeutics, Inc. (CAPR) is down 3% at $4.47 [4] - Mobile-Network Solutions (MNDR) is down 3% at $2.82 [4]

Findings Anticipated to Unlock Broad New Commercial Opportunities Across Water-Soluble Drug ClassesMELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced positive preclinical results showing its proprietary gel formulation achieved substantially higher bioavailability than a leading on-market reference antihistamine product. In a comparative pharmacokinetic stu ...

Core Insights - Gelteq Limited has initiated a preclinical animal trial in collaboration with Monash University to evaluate its proprietary formulation technology aimed at improving the oral delivery of oily and poorly soluble drugs [1][2][3] Company Overview - Gelteq is a clinical and science-based company headquartered in Melbourne, Australia, focusing on gel-based oral delivery solutions for various applications, including prescription drugs and nutraceuticals [4] Industry Context - Over 40% of marketed drugs and up to 90% of discovery candidates face challenges related to low solubility and variable bioavailability, which can lead to higher dosing and increased side effects [2] - Pharmaceutical companies invest more than USD 4 billion annually in technologies to enhance the delivery of oily and poorly soluble drugs, with strong projected growth through 2030 [2][8] Potential Commercial Applications - If successful in the trial, Gelteq aims to assist clients with a portfolio of oily and poorly soluble drugs through various commercial options, including pipeline salvage and lifecycle extension [3][6] - The company’s formulation technology could potentially improve adherence by reducing active pharmaceutical ingredient (API) dose size and food-effect dependence, leading to fewer side effects and more consistent patient outcomes [6]

Core Insights - Gelteq Limited has entered into a Product Development and Profit Share Agreement with Melbourne Health to develop new health products using high-amylose maize starch butyrylated (HAMSB), which has potential benefits in reducing bowel polyp growth and lowering bowel cancer risk [1][2][5] Group 1: Agreement Details - The collaboration aims to leverage Gelteq's gel-based oral delivery platform to create a ready-to-consume HAMSB product, enhancing patient compliance and efficacy in preventive health applications [4] - A profit-sharing model has been established under the Agreement, allowing Melbourne Health to receive a share of net profits from future product commercialization, recognizing its role in research and innovation [6] Group 2: Research Background - HAMSB has been the subject of significant research by Melbourne Health and CSIRO, with studies indicating its effectiveness in polyp initiation, suggesting a novel approach to colorectal health management [3] - Bowel cancer is a major health concern, being the fourth most common cancer diagnosis in Australia, affecting up to 1 in 20 people by age 85, highlighting the need for innovative prevention strategies [5] Group 3: Company Overview - Gelteq is a clinical and science-based company focused on developing gel-based oral delivery solutions for various applications, including prescription drugs and nutraceuticals, aiming to address challenges in conventional drug delivery [8]

Core Viewpoint - Gelteq Limited has successfully transitioned from research and development to active commercialization in the U.S. market through its collaboration with Healthy Extracts, marking a significant milestone for the company [2][3]. Company Overview - Gelteq Limited, headquartered in Melbourne, Australia, specializes in developing gel-based oral delivery solutions for various applications, including prescription drugs, nutraceuticals, pet care, and sports nutrition [4]. - The company's proprietary formulation technology addresses challenges in conventional drug delivery, such as taste masking, swallowing difficulties, and precision dosing [4]. Recent Developments - Healthy Extracts has launched products utilizing Gelteq's proprietary gel technology, which are the first to reach Gelteq's U.S. warehousing facility [2]. - The partnership with Healthy Extracts has evolved from initial warehousing and fulfillment arrangements to active sales and distribution, indicating growing momentum for Gelteq's gel delivery system [3]. Market Potential - The development highlights the growth potential of Gelteq's technology in large-scale wellness markets in the U.S. and its capability to meet consumer demand for innovative and clinically-informed products [2]. - The collaboration is expected to pave the way for additional products and partnerships in the U.S. market, enhancing Gelteq's presence and opportunities [3].

Company Overview - Gelteq Limited is a clinical and science-based company specializing in gel-based oral delivery solutions, headquartered in Melbourne, Australia [5] - The company is focused on developing and commercializing gel formulations for prescription drugs, nutraceuticals, pet care, and sports nutrition [5] Product Development - Gelteq plans to commence a preclinical bioequivalence study in September 2025 to evaluate a novel gel-based formulation of a widely used antihistamine for allergy treatment [1] - If preclinical results are successful, the company anticipates advancing to human clinical trials targeting FDA approval via the 505(b)(2) regulatory pathway [2] Market Opportunity - Allergic conditions affect over 50 million people annually in the United States, indicating a significant market for allergy treatments [3] - The global antihistamine market was valued at approximately USD 9 billion in 2023, growing at a 6% CAGR, projected to reach over USD 12 billion by 2028 [3][4] - Demand for antihistamines spans pediatric, adult, and animal health sectors, reflecting diverse applications for these therapies [3] Competitive Advantage - Gelteq's proprietary gel formulations aim to address limitations of traditional tablets and syrups, such as palatability for children, swallowing difficulties for the elderly, and precise dosing needs in veterinary medicine [4] - The innovative gel technology offers advantages in taste masking, ease of administration, and flexible dosing, particularly relevant in pediatric and veterinary care [5]